OBJECTIVE: To investigate risk factors for radiation-induced pneumonitis (RP) after hypofractionated stereotactic body radiotherapy (SBRT) in patients with lung tumours. METHODS: From May 2004 to January 2016, 66 patients with 71 primary or metastatic lung tumours were treated with SBRT; these 71 cases were retrospectively analyzed for RP. To explore the risk factors for RP, the following factors were investigated: age, sex, performance status, operability, number of treatments, respiratory gating, pulmonary emphysema, tumour location and subclinical interstitial lung disease (ILD). Irradiated underlying lung volumes of more than 5 Gy, 10 Gy, 20 Gy and 30 Gy (Lung V5, V10, V20 and V30), mean lung dose and volumes of gross tumour volume (in cubic centimetre) and planning target volume were calculated for possible risk factors of RP. RESULTS: The median follow-up period was 32 months. RP of Grade 2 or more, according to the Common Terminology Criteria for Adverse Events v. 4.0, was detected in 6 (8.4%) of the 71 cases. Grade 5 RP was identified in two cases. Of the risk factors of RP, subclinical ILD was the only factor significantly associated with the occurrence of RP of Grade 2 or more (p < 0.001). Both cases with Grade 5 RP had ILD with a honeycombing image. CONCLUSION: Subclinical ILD was the only significant factor for Grade 2-5 RP. In addition, the cases with honeycombing had a high potential for fatality related to severe RP. Patients with subclinical ILD should be carefully monitored for the occurrence of severe RP after SBRT. Advances in knowledge: Hypofractionated SBRT for primary or metastatic lung tumours provides a high local control rate and safe treatment.
OBJECTIVE: To investigate risk factors for radiation-induced pneumonitis (RP) after hypofractionated stereotactic body radiotherapy (SBRT) in patients with lung tumours. METHODS: From May 2004 to January 2016, 66 patients with 71 primary or metastatic lung tumours were treated with SBRT; these 71 cases were retrospectively analyzed for RP. To explore the risk factors for RP, the following factors were investigated: age, sex, performance status, operability, number of treatments, respiratory gating, pulmonary emphysema, tumour location and subclinical interstitial lung disease (ILD). Irradiated underlying lung volumes of more than 5 Gy, 10 Gy, 20 Gy and 30 Gy (Lung V5, V10, V20 and V30), mean lung dose and volumes of gross tumour volume (in cubic centimetre) and planning target volume were calculated for possible risk factors of RP. RESULTS: The median follow-up period was 32 months. RP of Grade 2 or more, according to the Common Terminology Criteria for Adverse Events v. 4.0, was detected in 6 (8.4%) of the 71 cases. Grade 5 RP was identified in two cases. Of the risk factors of RP, subclinical ILD was the only factor significantly associated with the occurrence of RP of Grade 2 or more (p < 0.001). Both cases with Grade 5 RP had ILD with a honeycombing image. CONCLUSION: Subclinical ILD was the only significant factor for Grade 2-5 RP. In addition, the cases with honeycombing had a high potential for fatality related to severe RP. Patients with subclinical ILD should be carefully monitored for the occurrence of severe RP after SBRT. Advances in knowledge: Hypofractionated SBRT for primary or metastatic lung tumours provides a high local control rate and safe treatment.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: K Goto; T Kodama; I Sekine; R Kakinuma; K Kubota; F Hojo; T Matsumoto; H Ohmatsu; H Ikeda; M Ando; Y Nishiwaki Journal: Lung Cancer Date: 2001-10 Impact factor: 5.705
Authors: Fiori Alite; Neelam Balasubramanian; William Adams; Murat Surucu; Ibrahim Mescioglu; Matthew M Harkenrider Journal: Am J Clin Oncol Date: 2018-06 Impact factor: 2.339
Authors: C M Roberts; E Foulcher; J J Zaunders; D H Bryant; J Freund; D Cairns; R Penny; G W Morgan; S N Breit Journal: Ann Intern Med Date: 1993-05-01 Impact factor: 25.391
Authors: Vitali Moiseenko; Jimm Grimm; Ellen Yorke; Andrew Jackson; Anthony Yip; Minh-Phuong Huynh-Le; Anand Mahadevan; Kenneth Forster; Michael T Milano; Jona A Hattangadi-Gluth Journal: Cureus Date: 2020-10-05
Authors: Ajay Sheshadri; Alberto A Goizueta; Vickie R Shannon; David London; Guillermo Garcia-Manero; Hagop M Kantarjian; Farhad Ravandi-Kashani; Tapan M Kadia; Marina Y Konopleva; Courtney D DiNardo; Sherry Pierce; Abdulrazzak Zarifa; Aya A Albittar; Linda L Zhong; Fechukwu O Akhmedzhanov; Muhammad H Arain; Mansour Alfayez; Ahmad Alotaibi; Mehmet Altan; Aung Naing; Tito R Mendoza; Myrna C B Godoy; Girish Shroff; Sang T Kim; Saadia A Faiz; Dimitrios P Kontoyiannis; Fareed Khawaja; Kristofer Jennings; Naval G Daver Journal: Cancer Date: 2022-04-22 Impact factor: 6.921
Authors: Vitali Moiseenko; Lawrence B Marks; Jimm Grimm; Andrew Jackson; Michael T Milano; Jona A Hattangadi-Gluth; Minh-Phuong Huynh-Le; Niclas Pettersson; Ellen Yorke; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-23 Impact factor: 8.013
Authors: Khaled Bousabarah; Oliver Blanck; Susanne Temming; Maria-Lisa Wilhelm; Mauritius Hoevels; Wolfgang W Baus; Daniel Ruess; Veerle Visser-Vandewalle; Maximilian I Ruge; Harald Treuer; Martin Kocher Journal: Radiat Oncol Date: 2021-04-16 Impact factor: 3.481